MoonLake's sonelokimab hits HiSCR75 with 29 ppt delta (p=0.0002) in Phase 2 HS trial

MoonLake Immunotherapeutics

Primary endpoint HiSCR75 met with 29 ppt delta vs placebo (p=0.0002) at week 12.
HiSCR50 achieved 38 ppt delta (p<0.0001), highest delta observed for any molecule in HS.
Secondary endpoints including HiSCR90, IHS4, and patient-reported pain/quality of life met statistical significance.
Safety profile consistent with known IL-17 inhibitor class; no new safety signals observed.
Dose of 120mg performed similarly to 240mg; 120mg considered optimal for further development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.